BioMarin: Gene Therapy Pipeline Driving Valuation Upside [Seeking Alpha]
BioMarin Pharmaceutical Inc. (BMRN)
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.biomarin.com
Company Research
Source: Seeking Alpha
Summary Screen shot from Forbes article linked BioMarin Pharmaceutical ( BMRN ) reported better than expected 2Q18 revenue and earnings though left guidance unchanged for calendar 2018. Palynziq was FDA-approved in May. BioMarin is targeting 2020 revenue of approximately $2 billion which is consistent with the June 2018 revenue growth of 16%. These results alone don’t justify the 20% rally since the first quarter results were announced. The most likely driver of this increase is the progress in gene therapy with Valoctocogene Roxaparvovec or BMN 270 for hemophilia A leading the way. This article is part of a series on genomic medicine which is poised to transform healthcare over the next two decades. My first article entitled Genomic Medicine: Catch the Gene Therapy Wave is a primer providing context for this article. June 2018 results BioMarin results for the June 2018 quarter were solid, beating both revenue and net loss consensus expectat
Show less
Read more
Impact Snapshot
Event Time:
BMRN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMRN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMRN alerts
High impacting BioMarin Pharmaceutical Inc. news events
Weekly update
A roundup of the hottest topics
BMRN
News
- World Hemophilia Day 2024"Equitable access for all: recognizing all bleeding disorders"PR Web
- World Hemophilia Day 2024"Equitable access for all: recognizing all bleeding disorders" [Yahoo! Finance]Yahoo! Finance
- First clinical trial of vosoritide for children with hypochondroplasia shows increased growth [Yahoo! Finance]Yahoo! Finance
- BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ETPR Newswire
- Jean-Jacques Bienaimé Appointed Chairman of the Board at Owkin [Yahoo! Finance]Yahoo! Finance
BMRN
Earnings
- 2/22/24 - Beat
BMRN
Sec Filings
- 4/15/24 - Form 4
- 4/12/24 - Form 4
- 4/12/24 - Form 144
- BMRN's page on the SEC website